ClinicalTrials.gg
CompletedNCT06240741Updated Feb 3, 2026Results posted

A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

A Phase 3 interventional study of [68Ga]Ga-DOTA-TATE and 68Ge/68Ga Generator in Neuroendocrine Neoplasms, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Japan. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hypersensitivity by Novartis — none open to participants now, none under way, none of them phase 3. Hypersensitivity · Novartis.

Enrollment
5th of 13
71 · median 40
Started
2024
the only one that year
Phase 3
2 of 13
none open now
Registered
13th of 13
by date

Among the 13 studies in Hypersensitivity by Novartis, this one is the 5th largest by enrollment, is the only one that started in 2024, is one of 2 in phase 3, and was the 13th registered.

Hypersensitivity

1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.

Browse Hypersensitivity studies →

Open to participants now

None of the 13 studies in Hypersensitivity by Novartis is open now. The open studies under Hypersensitivity, anywhere →

Who these studies take

Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Hypersensitivity by Novartis as a file.
02

Study summary

The purpose of this study was to evaluate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in patients with neuroendocrine neoplasms (NENs) and healthy volunteers (HVs).

The data from this study was collected in order to provide the evidence for diagnosis of [68Ga]Ga-DOTA-TATE PET/CT imaging in patient with NENs in Japan.

Read the detailed description

A total of 71 participants (48 patients with confirmed/suspected NENs and 23 HVs) were enrolled to ensure that at least 70 participants (47 patients with confirmed/suspected NENs and 23 HVs) were evaluable for the co-primary endpoints. All enrolled participants were administered [68Ga]Ga-DOTA-TATE and PET/CT scan.

The co-primary endpoints of the subject-level sensitivity and the subject-level specificity were assessed by comparing the central reading results of the [68Ga]Ga-DOTA-TATE PET/CT scan to the central reading results of Conventional imaging (CIM).

03

Conditions studied

  • Neuroendocrine Neoplasms

Browse trials for

Keywords

  • [68Ga]Ga-DOTA-TATE
  • Neuroendocrine Neoplasms (NENs)
  • Positron Emission Tomography (PET)
  • Computerized Tomography (CT)
  • PET/CT
  • Diagnostic performance
  • Sensitivity
  • Specificity
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Signed must have been obtained prior to participation in the study
  2. Participants must have been adults >= 18 years of age
  3. performance status 0-2
  4. For patient with NENs only: Participants were to be confirmed NENs based on histopathology, imaging and other relevant examination, or with suspected NENs which localization could not have been confirmed by CIM
  5. For HVs only: Male or female participant in good health condition as determined by no findings from medical history, physical examination, vital signs, lab test and
  6. Women of must havehad a negative urine or blood pregnancy test.

Key Exclusion Criteria:

  1. Inability to complete the needed and conventional imaging due to any reason (severe claustrophobia, inability to lie still for the entire imaging time, etc.)
  2. Any additional medical condition, serious intercurrent illness, concomitant cancer or other extenuating circumstance that, in the opinion of the Investigator, would indicate a significant risk to safety or impair study participation
  3. Known allergy, , or intolerance to [68Ga]Ga-DOTA-TATE and [111In]In-Pentetreotide
  4. Therapeutic use of any somatostatin analogue except for the following

    • Short-acting analogs of somatostatin can be used up to 24 hours before injection of [68Ga]Ga-DOTA-TATE.
    • Long-acting analogs of somatostatin can be used up to 28 days before injection of [68Ga]Ga-DOTA-TATE.
  5. Prior administration of a radiopharmaceutical unless 10 or more half-lives have elapsed before injection of [68Ga]Ga-DOTA-TATE
  6. Use of other investigational drugs within 30 days before screening
  7. Participants who were pregnant.
  8. Participants who were lactating.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    [68Ga]Ga-DOTA-TATE

    All eligible participants will receive \[68Ga\]Ga-DOTA-TATE via intravenous injection at a dose of 2 MBq/kg (0.054 mCi/kg) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)

    Drug: [68Ga]Ga-DOTA-TATE · Drug: 68Ge/68Ga Generator

Interventions

  • Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1).

    Also known as: AAA501

  • Drug68Ge/68Ga Generator

    Radionuclide generator

    Also known as: EZR001

06

What researchers measure

Primary outcomes

  1. Number of [68Ga]Ga-DOTA-TATE Positive Participants (TP Participants) Among CIM Positive Participants (TP or FN Participants)

    Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants). * TP participants were those who showed at least one lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read. * FN participants were those who did not show any lesions based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but showed at least one lesion based on CIM by central read. True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\]

    Time frame: Day 1

  2. Number of [68Ga]Ga-DOTA-TATE Negative Participants (TN Participants) Among CIM Negative Participants (TN or FP Participants)

    Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants). * TN participants were those who did not show any lesions based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read. * FP participants were those who showed at least one lesion based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but did not show any lesions based on CIM by central read. True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\]

    Time frame: Day 1

  3. Subject-level Sensitivity

    Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants). True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\] Sensitivity = TP / (TP + FN)

    Time frame: Day 1

  4. Subject-level Specificity

    Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants). True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\] Specificity = TN / (TN + FP).

    Time frame: Day 1

Secondary outcomes

  1. Number of Participants Who Are Positive on Both [68Ga]Ga-DOTA-TATE PET/CT Imagings and CIM (TP Participants) Among Participants Who Are Positive on [68Ga]Ga-DOTA TATE PET/CT Imaging (TP or FP Participants)

    Subject-level positive predictive values (PPV) is defined as the proportion of TP participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP or FP participants).

    Time frame: Day 1

  2. Number of Participants Who Are Negative on Both [68Ga]Ga-DOTA-TATE PET/CT Imaging and CIM (TN Participants) Among Participants Who Are Negative on [68Ga]Ga-DOTA-TATE PET/CT Imaging (TN or FN Participants)

    Subject-level NPV was defined as the proportion of TN participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN or FN participants).

    Time frame: Day 1

  3. Subject-level PPV

    Subject-level positive predictive values (PPV) is defined as the proportion of TP participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP or FP participants). PPV (Subject-level positive predictive values) = TP / (TP + FP)

    Time frame: Day 1

  4. Subject-level NPV

    Subject-level NPV was defined as the proportion of TN participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN or FN participants). NPV (Subject-level negative predictive values) = TN / (TN + FN)

    Time frame: Day 1

  5. Participants Who Have Consistent Results (i.e. TP or TN Participants) Among All Participants Assessed by [68Ga]Ga-DOTA-TATE PET/CT Imaging and CIM - Subject-level Accuracy

    Subject-level accuracy is defined as the proportion of TP and TN participants among all patients in the EFF (i.e. TP+TN+FP+FN participants). Accuracy = (TP + TN) / (TP + TN + FP + FN).

    Time frame: Day 1

  6. Region-level Sensitivity

    Region-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive regions (TP regions) among CIM positive regions (i.e. TP or FN regions). Sensitivity = TP / (TP + FN)

    Time frame: Day 1

  7. Region-level Specificity

    Region-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative regions (TN regions) among CIM negative regions (i.e. TN or FP regions). Specificity = TN / (TN + FP) Note: Even when a participant is categorized as positive in subject-level, he/she can still have negative results in region-level. e.g. When only Liver is positive and other regions are negative, the participant is categorized as positive in subject-level. As all participants had at least one CIM-negative region and were included in the table, the number of participants analyzed is 71.

    Time frame: Day 1

  8. Region-level Positive Predictive Values (PPV)

    Region-level PPV is defined as the proportion of regions which are positive on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM (TP regions) among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive regions (i.e. TP or FP regions). Region-level positive predictive values (PPV) = TP / (TP +FP)

    Time frame: Day 1

  9. Region-level Negative Predictive Values (NPV)

    Region-level NPV is defined as the proportion of regions which are negative on both \[68Ga\]Ga- DOTA-TATE PET/CT imaging and CIM (TN regions) among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative regions (i.e. TN or FN regions). Region-level negative predictive values (NPV) = TN / (TN + FN) Note: Even when a participant is categorized as positive in subject-level, he/she can still have negative results in region-level. e.g. When only Liver is positive and other regions are negative, the participants is categorized as positive in subject-level. As all participants had at least one negative region by Ga-DOTA-TATE PET/CT and were included in the table, the number of participants analyzed = 71.

    Time frame: Day 1

  10. Region-level Accuracy

    Region-level accuracy is defined as the proportion of regions which are CIM and \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive (TP regions) or negative (TN regions) among regions detected by CIM and \[68Ga\]Ga-DOTA-TATE PET/CT imaging (i.e. TP+TN+FP+FN regions). Accuracy = (TP + TN) / (TP + TN + FP + FN).

    Time frame: Day 1

  11. Region-level True Positive

    TP regions were the regions which showed at least one lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read

    Time frame: Day 1

  12. Region-level False Negative

    FN regions were the regions which did not show any lesions based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but show at least one lesion based on CIM by central read.

    Time frame: Day 1

  13. Region-level False Positive

    FP regions were the regions which showed at least one lesion based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but do not showed any lesion based on CIM by central read.

    Time frame: Day 1

  14. Region-level True Negative

    TN regions were the regions which did not show any lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read.

    Time frame: Day 1

  15. Number of Participants Who Underwent a Change in Intended Treatment Plan Attributed to the [68Ga]Ga-DOTA-TATE PET/CT Imaging as Assessed by Pre and Post Imaging Questionnaires

    Numbers of participants for each intended treatment plan collected from physician at pre and post \[68Ga\]Ga-DOTA-TATE PET/CT imaging will be summarized.

    Time frame: Before and after imaging on Day 1

  16. Inter-reader Agreement on [68Ga]Ga-DOTA-TATE PET/CT Imaging

    The assessment of \[68Ga\]Ga-DOTA-TATE PET/CT images set was compared among the 3 independent readers.

    Time frame: Day 1

  17. Inter-reader Variability (%) on [68Ga]Ga-DOTA-TATE PET/CT Imaging

    Inter-reader variability for \[68Ga\]Ga-DOTA-TATE PET/CT imaging is defined as agreement rate among reader determinations. As assessed by Fleiss' Kappa statistics. Inter-reader variability (%) and its normality 95% CI is presented.

    Time frame: Day 1

  18. Incidence of Treatment Emergent Adverse Event (TEAE) Within 8 Days After [68Ga]Ga-DOTATATE Administration

    An adverse event (AE) is any untoward medical occurrence (e.g., any occurrence of unfavorable and unintended sign(s), symptom(s) or medical condition, including abnormal laboratory findings, or worsening of any pre-existing sign(s), symptom(s) or medical condition) in a participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of any treatment used in this study. This includes events reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).

    Time frame: For treated pts: AEs are reported from the single dose of study treatment plus 8 days post treatment, up to a maximum timeframe of 9 days. For HV pts: AEs are reported from the study start plus 8 days, up to a maximum timeframe of 9 days.

  19. Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUCinf) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-inf) will be listed and summarized using descriptive statistics.

    Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)

  20. Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUClast will be listed and summarized using descriptive statistics.

    Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)

  21. Observed Maximum Plasma Concentration (Cmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.

    Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)

  22. Time of Maximum Observed Drug Concentration Occurrence (Tmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Tmax will be listed and summarized using descriptive statistics.

    Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)

  23. Terminal Elimination Half-life (T1/2) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. The half-live will be listed and summarized using descriptive statistics.

    Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)

  24. Total Systemic Clearance for Intravenous Administration (CL) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. CL will be listed and summarized using descriptive statistics.

    Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)

  25. Volume of Distribution During the Terminal Phase Following Intravenous Elimination (Vz) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Vz will be listed and summarized using descriptive statistics.

    Time frame: Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)

  26. Lesion-level Concordance Rate for SSTR Between [68Ga]Ga-DOTA-TATE PET/CT Imaging Local Read and Local Histopathology Result Among Lesions That Local Histopathology Result Are Available

    The lesion-level concordance rate for SSTR between \[68Ga\]Ga-DOTA-TATE PET/CT imaging local read and local histopathology result among legions which is available, will be calculated. The rate is defined as the proportion of lesions which are positive or negative on both local read of \[68Ga\]Ga-DOTA-TATE PET/CT imaging and local histopathology among lesions detected by local histopathology.

    Time frame: Day 1 to Day 30

  27. Lesion-level Concordance Rate for SSTR Between [68Ga]Ga-DOTA-TATE PET/CT Imaging Local Read and Local Histopathology Result Among Lesions That Local Histopathology Result Are Available - Concordance Rate

    The lesion-level concordance rate for SSTR between \[68Ga\]Ga-DOTA-TATE PET/CT imaging local read and local histopathology result among legions which is available, will be calculated. The rate is defined as the proportion of lesions which are positive or negative on both local read of \[68Ga\]Ga-DOTA-TATE PET/CT imaging and local histopathology among lesions detected by local histopathology.

    Time frame: Day 1 to Day 30

07

Results

Posted Feb 3, 2026

Participant flow

This study was not designed to compare efficacy between NEN patients and HVs, but rather to assess sensitivity and specificity of Ga-DOTA-TATE PET/CT imaging against the CIM in the population which includes both of CIM positive and negative.

Participant flow — Overall Study
Milestone[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Started4823
Completed4823
Not completed00

Outcome measures

PrimaryNumber of [68Ga]Ga-DOTA-TATE Positive Participants (TP Participants) Among CIM Positive Participants (TP or FN Participants)

Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants). * TP participants were those who showed at least one lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read. * FN participants were those who did not show any lesions based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but showed at least one lesion based on CIM by central read. True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\]

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of [68Ga]Ga-DOTA-TATE Positive Participants (TP Participants) Among CIM Positive Participants (TP or FN Participants)
ParticipantsAll Participants
True Positive [TP]40
False Negative [FN]6
PrimaryNumber of [68Ga]Ga-DOTA-TATE Negative Participants (TN Participants) Among CIM Negative Participants (TN or FP Participants)

Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants). * TN participants were those who did not show any lesions based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read. * FP participants were those who showed at least one lesion based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but did not show any lesions based on CIM by central read. True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\]

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of [68Ga]Ga-DOTA-TATE Negative Participants (TN Participants) Among CIM Negative Participants (TN or FP Participants)
ParticipantsAll Participants
True Negative [TN]23
False Positive [FP]2
PrimarySubject-level Sensitivity

Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants). True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\] Sensitivity = TP / (TP + FN)

Time frame:
Day 1
Reported as:
Number · Sensitivity (%)
Subject-level Sensitivity
Sensitivity (%)All Participants
Subject-level Sensitivity87.0 (73.74 to 95.06)
PrimarySubject-level Specificity

Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants). True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\] Specificity = TN / (TN + FP).

Time frame:
Day 1
Reported as:
Number · Specificity (%)
Subject-level Specificity
Specificity (%)All Participants
Subject-level Specificity92.0 (73.97 to 99.02)
SecondaryNumber of Participants Who Are Positive on Both [68Ga]Ga-DOTA-TATE PET/CT Imagings and CIM (TP Participants) Among Participants Who Are Positive on [68Ga]Ga-DOTA TATE PET/CT Imaging (TP or FP Participants)

Subject-level positive predictive values (PPV) is defined as the proportion of TP participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP or FP participants).

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants Who Are Positive on Both [68Ga]Ga-DOTA-TATE PET/CT Imagings and CIM (TP Participants) Among Participants Who Are Positive on [68Ga]Ga-DOTA TATE PET/CT Imaging (TP or FP Participants)
ParticipantsAll Participants
True Positive [TP]40
False Positive [FP]2
SecondaryNumber of Participants Who Are Negative on Both [68Ga]Ga-DOTA-TATE PET/CT Imaging and CIM (TN Participants) Among Participants Who Are Negative on [68Ga]Ga-DOTA-TATE PET/CT Imaging (TN or FN Participants)

Subject-level NPV was defined as the proportion of TN participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN or FN participants).

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants Who Are Negative on Both [68Ga]Ga-DOTA-TATE PET/CT Imaging and CIM (TN Participants) Among Participants Who Are Negative on [68Ga]Ga-DOTA-TATE PET/CT Imaging (TN or FN Participants)
ParticipantsAll Participants
False Negative [FN]6
True Negative [TN]23
SecondarySubject-level PPV

Subject-level positive predictive values (PPV) is defined as the proportion of TP participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP or FP participants). PPV (Subject-level positive predictive values) = TP / (TP + FP)

Time frame:
Day 1
Reported as:
Number · PPV (%)
Subject-level PPV
PPV (%)All Participants
Subject-level PPV95.2 (83.84 to 99.42)
SecondarySubject-level NPV

Subject-level NPV was defined as the proportion of TN participants among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN or FN participants). NPV (Subject-level negative predictive values) = TN / (TN + FN)

Time frame:
Day 1
Reported as:
Number · NPV (%)
Subject-level NPV
NPV (%)All Participants
Subject-level NPV79.3 (60.28 to 92.01)
SecondaryParticipants Who Have Consistent Results (i.e. TP or TN Participants) Among All Participants Assessed by [68Ga]Ga-DOTA-TATE PET/CT Imaging and CIM - Subject-level Accuracy

Subject-level accuracy is defined as the proportion of TP and TN participants among all patients in the EFF (i.e. TP+TN+FP+FN participants). Accuracy = (TP + TN) / (TP + TN + FP + FN).

Time frame:
Day 1
Reported as:
Number · Accuracy (%)
Participants Who Have Consistent Results (i.e. TP or TN Participants) Among All Participants Assessed by [68Ga]Ga-DOTA-TATE PET/CT Imaging and CIM - Subject-level Accuracy
Accuracy (%)All Participants
Participants Who Have Consistent Results (i.e. TP or TN Participants) Among All Participants Assessed by [68Ga]Ga-DOTA-TATE PET/CT Imaging and CIM - Subject-level Accuracy88.7 (79.00 to 95.01)
SecondaryRegion-level Sensitivity

Region-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive regions (TP regions) among CIM positive regions (i.e. TP or FN regions). Sensitivity = TP / (TP + FN)

Time frame:
Day 1
Reported as:
Number · Sensitivity (%)
Region-level Sensitivity
Sensitivity (%)All Participants
Liver77.8 (60.85 to 89.88)
Pancreas42.9 (17.66 to 71.14)
Gastrointestinal tract0 (0 to 97.50)
Lymph nodes75.0 (47.62 to 92.73)
Other84.6 (54.55 to 98.08)
SecondaryRegion-level Specificity

Region-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative regions (TN regions) among CIM negative regions (i.e. TN or FP regions). Specificity = TN / (TN + FP) Note: Even when a participant is categorized as positive in subject-level, he/she can still have negative results in region-level. e.g. When only Liver is positive and other regions are negative, the participant is categorized as positive in subject-level. As all participants had at least one CIM-negative region and were included in the table, the number of participants analyzed is 71.

Time frame:
Day 1
Reported as:
Number · Specificity(%)
Region-level Specificity
Specificity(%)All Participants
Liver97.1 (85.08 to 99.93)
Pancreas89.5 (78.48 to 96.04)
Gastrointestinal tract95.7 (87.98 to 99.11)
Lymph nodes83.6 (71.20 to 92.23)
Other94.8 (85.62 to 98.92)
SecondaryRegion-level Positive Predictive Values (PPV)

Region-level PPV is defined as the proportion of regions which are positive on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM (TP regions) among \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive regions (i.e. TP or FP regions). Region-level positive predictive values (PPV) = TP / (TP +FP)

Time frame:
Day 1
Reported as:
Number · PPV (%)
Region-level Positive Predictive Values (PPV)
PPV (%)All Participants
Liver96.6 (82.24 to 99.91)
Pancreas50.0 (21.09 to 78.91)
Gastrointestinal tract0 (0 to 70.76)
Lymph nodes57.1 (34.02 to 78.18)
Other78.6 (49.20 to 95.34)
SecondaryRegion-level Negative Predictive Values (NPV)

Region-level NPV is defined as the proportion of regions which are negative on both \[68Ga\]Ga- DOTA-TATE PET/CT imaging and CIM (TN regions) among \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative regions (i.e. TN or FN regions). Region-level negative predictive values (NPV) = TN / (TN + FN) Note: Even when a participant is categorized as positive in subject-level, he/she can still have negative results in region-level. e.g. When only Liver is positive and other regions are negative, the participants is categorized as positive in subject-level. As all participants had at least one negative region by Ga-DOTA-TATE PET/CT and were included in the table, the number of participants analyzed = 71.

Time frame:
Day 1
Reported as:
Number · NPV (%)
Region-level Negative Predictive Values (NPV)
NPV (%)All Participants
Liver81.0 (65.88 to 91.40)
Pancreas86.4 (75.02 to 93.96)
Gastrointestinal tract98.5 (92.08 to 99.96)
Lymph nodes92.0 (80.77 to 97.78)
Other96.5 (87.89 to 99.57)
SecondaryRegion-level Accuracy

Region-level accuracy is defined as the proportion of regions which are CIM and \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive (TP regions) or negative (TN regions) among regions detected by CIM and \[68Ga\]Ga-DOTA-TATE PET/CT imaging (i.e. TP+TN+FP+FN regions). Accuracy = (TP + TN) / (TP + TN + FP + FN).

Time frame:
Day 1
Reported as:
Number · accuracy (%)
Region-level Accuracy
accuracy (%)All Participants
Liver87.3 (77.30 to 94.04)
Pancreas80.3 (69.14 to 88.78)
Gastrointestinal tract94.4 (86.20 to 98.44)
Lymph nodes81.7 (70.73 to 89.87)
Other93.0 (84.33 to 97.67)
SecondaryRegion-level True Positive

TP regions were the regions which showed at least one lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read

Time frame:
Day 1
Reported as:
Count of participants · Participants
Region-level True Positive
ParticipantsAll Participants
Liver28
Pancreas6
Gastrointestinal tract0
Lymph nodes12
Other11
SecondaryRegion-level False Negative

FN regions were the regions which did not show any lesions based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but show at least one lesion based on CIM by central read.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Region-level False Negative
ParticipantsAll Participants
Liver8
Pancreas8
Gastrointestinal tract1
Lymph nodes4
Other2
SecondaryRegion-level False Positive

FP regions were the regions which showed at least one lesion based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but do not showed any lesion based on CIM by central read.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Region-level False Positive
ParticipantsAll Participants
Liver1
Pancreas6
Gastrointestinal tract3
Lymph nodes9
Other3
SecondaryRegion-level True Negative

TN regions were the regions which did not show any lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Region-level True Negative
ParticipantsAll Participants
Liver34
Pancreas51
Gastrointestinal tract67
Lymph nodes46
Other55
SecondaryNumber of Participants Who Underwent a Change in Intended Treatment Plan Attributed to the [68Ga]Ga-DOTA-TATE PET/CT Imaging as Assessed by Pre and Post Imaging Questionnaires

Numbers of participants for each intended treatment plan collected from physician at pre and post \[68Ga\]Ga-DOTA-TATE PET/CT imaging will be summarized.

Time frame:
Before and after imaging on Day 1
Reported as:
Count of participants · Participants
Number of Participants Who Underwent a Change in Intended Treatment Plan Attributed to the [68Ga]Ga-DOTA-TATE PET/CT Imaging as Assessed by Pre and Post Imaging Questionnaires
Participants[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Planned treatment of Chemotherapy - Before imaging8—
Planned treatment of Lutathera - Before imaging14—
Planned treatment of Observation/surveillance - Before imaging6—
Planned treatment of Radiation - Before imaging0—
Planned treatment of Somatostatin Analog - Before imaging15—
Planned treatment of Surgery - Before imaging5—
Planned treatment of Other - Before imaging2—
Planned treatment of Chemotherapy - After imaging6—
Planned treatment of Lutathera - After imaging17—
Planned treatment of Observation/surveillance - After imaging7—
Planned treatment of Radiation - After imaging2—
Planned treatment of Somatostatin Analog - After imaging15—
Planned treatment of Surgery - After imaging4—
Planned treatment of Other - After imaging2—
Participants with no change in treatment plans - After imaging30—
- Chemotherapy - After imaging4—
- Chemotherapy, Somatostatin Analog - After imaging2—
- Lutathera -After imaging10—
-Observation/surveillance -After imaging3—
- Somatostatin Analog -After imaging8—
- Surgery -After imaging2—
- Other -After imaging1—
Participants with change in treatment plans18—
-Chemotherapy Before - Lutathera After2—
-Lutathera Before - Lutathera, Radiation After1—
- Lutathera Before - Lutathera, Surgery After1—
-Lutathera Before - Observation/surveillance After1—
- Lutathera Before - Radiation After1—
- Observation/surveillance Before - Lutathera After1—
- Observation/surveillance Before - Observation/surveillance After1—
- Observation/surveillance Before - Somatostatin Analog After1—
- Somatostatin Analog Before - Lutathera After1—
- Somatostatin Analog Before - Observation/surveillance After1—
- Somatostatin Analog Before - Somatostatin Analog After3—
- Surgery Before - Lutathera, Surgery After1—
-Surgery Before - Observation/surveillance After1—
- Surgery Before - Somatostatin Analog After1—
- Other Before - Other After1—
SecondaryInter-reader Agreement on [68Ga]Ga-DOTA-TATE PET/CT Imaging

The assessment of \[68Ga\]Ga-DOTA-TATE PET/CT images set was compared among the 3 independent readers.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Inter-reader Agreement on [68Ga]Ga-DOTA-TATE PET/CT Imaging
ParticipantsAll Participants
Central Reader 1 Positive54
Central Reader 2 Positive42
Central Reader 3 Positive41
Central Reader 1 Negative17
Central Reader 2 Negative29
Central Reader 3 Negative30
SecondaryInter-reader Variability (%) on [68Ga]Ga-DOTA-TATE PET/CT Imaging

Inter-reader variability for \[68Ga\]Ga-DOTA-TATE PET/CT imaging is defined as agreement rate among reader determinations. As assessed by Fleiss' Kappa statistics. Inter-reader variability (%) and its normality 95% CI is presented.

Time frame:
Day 1
Reported as:
Number · Inter-reader variability (%)
Inter-reader Variability (%) on [68Ga]Ga-DOTA-TATE PET/CT Imaging
Inter-reader variability (%)All Participants
Inter-reader Variability (%) on [68Ga]Ga-DOTA-TATE PET/CT Imaging65.2 (51.79 to 78.65)
SecondaryIncidence of Treatment Emergent Adverse Event (TEAE) Within 8 Days After [68Ga]Ga-DOTATATE Administration

An adverse event (AE) is any untoward medical occurrence (e.g., any occurrence of unfavorable and unintended sign(s), symptom(s) or medical condition, including abnormal laboratory findings, or worsening of any pre-existing sign(s), symptom(s) or medical condition) in a participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of any treatment used in this study. This includes events reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).

Time frame:
For treated pts: AEs are reported from the single dose of study treatment plus 8 days post treatment, up to a maximum timeframe of 9 days. For HV pts: AEs are reported from the study start plus 8 days, up to a maximum timeframe of 9 days.
Reported as:
Count of participants · Participants
Incidence of Treatment Emergent Adverse Event (TEAE) Within 8 Days After [68Ga]Ga-DOTATATE Administration
Participants[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Adverse events (AEs)82
Adverse events - Treatment-related10
Serious Adverse events (SAEs)20
Serious Adverse events Treatment-related00
Fatal SAEs00
Fatal SAEs - Treatment-related00
AEs requiring additional therapy30
SecondaryArea Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUCinf) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUC(0-inf) will be listed and summarized using descriptive statistics.

Time frame:
Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUCinf) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
h*ng/mL[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUCinf) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]0.420 ± 25.5—
SecondaryArea Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. AUClast will be listed and summarized using descriptive statistics.

Time frame:
Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Reported as:
Geometric mean · h*ng/mL
Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
h*ng/mL[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]0.304 ± 26.3—
SecondaryObserved Maximum Plasma Concentration (Cmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.

Time frame:
Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Reported as:
Geometric mean · ng/mL
Observed Maximum Plasma Concentration (Cmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
ng/mL[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Observed Maximum Plasma Concentration (Cmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]0.656 ± 30.7—
SecondaryTime of Maximum Observed Drug Concentration Occurrence (Tmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Tmax will be listed and summarized using descriptive statistics.

Time frame:
Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Reported as:
Median · hour
Time of Maximum Observed Drug Concentration Occurrence (Tmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
hour[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Time of Maximum Observed Drug Concentration Occurrence (Tmax) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]0.0750 (0.0333 to 0.100)—
SecondaryTerminal Elimination Half-life (T1/2) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. The half-live will be listed and summarized using descriptive statistics.

Time frame:
Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Reported as:
Geometric mean · hour
Terminal Elimination Half-life (T1/2) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
hour[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Terminal Elimination Half-life (T1/2) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]1.77 ± 26.3—
SecondaryTotal Systemic Clearance for Intravenous Administration (CL) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. CL will be listed and summarized using descriptive statistics.

Time frame:
Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Reported as:
Geometric mean · L/h
Total Systemic Clearance for Intravenous Administration (CL) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
L/h[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Total Systemic Clearance for Intravenous Administration (CL) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]26.0 ± 32.5—
SecondaryVolume of Distribution During the Terminal Phase Following Intravenous Elimination (Vz) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]

Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Vz will be listed and summarized using descriptive statistics.

Time frame:
Day 1 (5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 180 min)
Reported as:
Geometric mean · L
Volume of Distribution During the Terminal Phase Following Intravenous Elimination (Vz) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]
L[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Volume of Distribution During the Terminal Phase Following Intravenous Elimination (Vz) of [68Ga]Ga-DOTA-TATE [Mass-based Concentration]66.2 ± 53.5—
SecondaryLesion-level Concordance Rate for SSTR Between [68Ga]Ga-DOTA-TATE PET/CT Imaging Local Read and Local Histopathology Result Among Lesions That Local Histopathology Result Are Available

The lesion-level concordance rate for SSTR between \[68Ga\]Ga-DOTA-TATE PET/CT imaging local read and local histopathology result among legions which is available, will be calculated. The rate is defined as the proportion of lesions which are positive or negative on both local read of \[68Ga\]Ga-DOTA-TATE PET/CT imaging and local histopathology among lesions detected by local histopathology.

Time frame:
Day 1 to Day 30
Reported as:
Number · lesions
Lesion-level Concordance Rate for SSTR Between [68Ga]Ga-DOTA-TATE PET/CT Imaging Local Read and Local Histopathology Result Among Lesions That Local Histopathology Result Are Available
lesions[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Total number of lesions with histopathology assessments11—
Positive Result of SSTR by histopathology8—
Negative Result of SSTR by histopathology3—
Positive Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read11—
Negative Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read0—
+ Result of SSTR by histopathology - + Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read8—
+ Result of SSTR by histopathology & -Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read0—
- Result of SSTR by histopathology & + Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read3—
- Result of SSTR by histopathology & - Result of [68Ga]Ga-DOTA-TATE PET/CT imaging by local read0—
Lesions with concordant results8—
SecondaryLesion-level Concordance Rate for SSTR Between [68Ga]Ga-DOTA-TATE PET/CT Imaging Local Read and Local Histopathology Result Among Lesions That Local Histopathology Result Are Available - Concordance Rate

The lesion-level concordance rate for SSTR between \[68Ga\]Ga-DOTA-TATE PET/CT imaging local read and local histopathology result among legions which is available, will be calculated. The rate is defined as the proportion of lesions which are positive or negative on both local read of \[68Ga\]Ga-DOTA-TATE PET/CT imaging and local histopathology among lesions detected by local histopathology.

Time frame:
Day 1 to Day 30
Reported as:
Number · Concordance rate (%)
Lesion-level Concordance Rate for SSTR Between [68Ga]Ga-DOTA-TATE PET/CT Imaging Local Read and Local Histopathology Result Among Lesions That Local Histopathology Result Are Available - Concordance Rate
Concordance rate (%)[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Lesion-level Concordance Rate for SSTR Between [68Ga]Ga-DOTA-TATE PET/CT Imaging Local Read and Local Histopathology Result Among Lesions That Local Histopathology Result Are Available - Concordance Rate72.7 (39.03 to 93.98)—

Adverse events

Collected over Adverse events are reported from the single dose of study treatment plus 8 days post treatment, up to a maximum timeframe of 9 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENs0/48 (0%)2/48 (4.2%)8/48 (16.7%)
Healthy Volunteers0/23 (0%)0/23 (0%)2/23 (8.7%)
Most frequent serious events
Most frequent serious events
Event[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
Intra-abdominal haemorrhageGastrointestinal disorders1/480/23
VomitingGastrointestinal disorders1/480/23
Most frequent other events
Showing 10 of 15
Most frequent other events
Event[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy Volunteers
MalaiseGeneral disorders0/481/23
PresyncopeNervous system disorders0/481/23
NeutropeniaBlood and lymphatic system disorders1/480/23
PyrexiaGeneral disorders1/480/23
Liver disorderHepatobiliary disorders1/480/23
Aspartate aminotransferase increasedInvestigations1/480/23
Blood creatine phosphokinase increasedInvestigations1/480/23
Electrocardiogram PR prolongationInvestigations1/480/23
Electrocardiogram QT prolongedInvestigations1/480/23
Electrocardiogram ST-T segment abnormalInvestigations1/480/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy VolunteersTotal
<=18 years000
Between 18 and 65 years292251
>=65 years19120
Sex: Female, Male
Sex: Female, Male(Participants)[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy VolunteersTotal
Female231033
Male251338
Race (NIH/OMB)
Race (NIH/OMB)(Participants)[68Ga]Ga-DOTA-TATE / Confirmed/Suspected NENsHealthy VolunteersTotal
American Indian or Alaska Native000
Asian482371
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

8 sites
  • Novartis Investigative Site
    Kashiwa, Chiba 277 8577, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 060 8648, Japan
  • Novartis Investigative Site
    Kanazawa, Ishikawa-ken 920 8641, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa-ku 236-0004, Japan
  • Novartis Investigative Site
    Chuo Ku, Tokyo 1040045, Japan
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
  • Novartis Investigative Site
    Fukuoka, 813-0017, Japan
  • Novartis Investigative Site
    Kyoto, 6068507, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Dec 2024, 9 months.

Results were first posted in Feb 2026, 1 year 1 month after primary completion.

Of 32 industry-sponsored phase 3 interventional studies under Hypersensitivity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 9 months is below that.

Counting every sponsor, half of 42 studies reached it within 23 months; a quarter within 10 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 5, 2024
StartActual
Mar 21, 2024
Primary completionActual
Dec 27, 2024
CompletionActual
Dec 27, 2024
Results first posted
Feb 3, 2026
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06240741
Collaborators
Eckert & Ziegler Radiopharma GmbH
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Mar 21, 2024
Primary completion
Dec 27, 2024
Completion
Dec 27, 2024
Results posted
Feb 3, 2026
Last update
Feb 3, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion